Patents by Inventor Anne Laurent

Anne Laurent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune complexes comprising proteins of human immunodeficiency virus type 2 (HIV-2), antibodies against proteins of HIV-2, methods and kits employing proteins of HIV-2, and immunogenic compositions comprising proteins of HIV-2
    Publication number: 20070172927
    Abstract: Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp140, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing.
    Type: Application
    Filed: September 27, 2005
    Publication date: July 26, 2007
    Inventors: Luc Montagnier, Anne Laurent-Crawford, Bernard Krust, Ara Hovanessian, Marie-Anne Rey-Cuille
  • Dimer of the precursor of HIV-2 envelope glycoprotein
    Patent number: 5312902
    Abstract: Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp140, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: May 17, 1994
    Assignees: Institut Pasteur, C.N.R.S.
    Inventors: Luc Montagnier, Ara Hovanessian, Anne Laurent, Bernard Krust, Marie-Anne Rey